These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11002427)

  • 1. Deletion and tandem duplication of exons 2 - 7 in the epidermal growth factor receptor gene of a human malignant glioma.
    Fenstermaker RA; Ciesielski MJ
    Oncogene; 2000 Sep; 19(39):4542-8. PubMed ID: 11002427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function.
    Ciesielski MJ; Fenstermaker RA
    Oncogene; 2000 Feb; 19(6):810-20. PubMed ID: 10698499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tandem duplication of the epidermal growth factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells.
    Fenstermaker RA; Ciesielski MJ; Castiglia GJ
    Oncogene; 1998 Jul; 16(26):3435-43. PubMed ID: 9692551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
    Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localization of aberrant messenger RNA of epidermal growth factor receptor (EGFR) in malignant glioma.
    Tsugu A; Kijima H; Yamazaki H; Ohnishi Y; Takamiya Y; Abe Y; Ueyama Y; Sato O; Tamaoki N; Nakamura M
    Anticancer Res; 1997; 17(3C):2225-32. PubMed ID: 9216693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations.
    Bremm A; Walch A; Fuchs M; Mages J; Duyster J; Keller G; Hermannstädter C; Becker KF; Rauser S; Langer R; von Weyhern CH; Höfler H; Luber B
    Cancer Res; 2008 Feb; 68(3):707-14. PubMed ID: 18245470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations.
    Arjona D; Bello MJ; Alonso ME; Aminoso C; Isla A; De Campos JM; Sarasa JL; Gutierrez M; Villalobo A; Rey JA
    Neuropathol Appl Neurobiol; 2005 Aug; 31(4):384-94. PubMed ID: 16008822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
    Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
    Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR.
    Luwor RB; Zhu HJ; Walker F; Vitali AA; Perera RM; Burgess AW; Scott AM; Johns TG
    Oncogene; 2004 Aug; 23(36):6095-104. PubMed ID: 15221011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
    Lorimer IA; Wikstrand CJ; Batra SK; Bigner DD; Pastan I
    Clin Cancer Res; 1995 Aug; 1(8):859-64. PubMed ID: 9816055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas.
    Xu K; Shu HK
    Cancer Res; 2007 Jul; 67(13):6121-9. PubMed ID: 17616668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
    Bax DA; Gaspar N; Little SE; Marshall L; Perryman L; Regairaz M; Viana-Pereira M; Vuononvirta R; Sharp SY; Reis-Filho JS; Stávale JN; Al-Sarraj S; Reis RM; Vassal G; Pearson AD; Hargrave D; Ellison DW; Workman P; Jones C
    Clin Cancer Res; 2009 Sep; 15(18):5753-61. PubMed ID: 19737945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.
    Yang B; Chen J; Zhang X; Cao J
    Auris Nasus Larynx; 2009 Dec; 36(6):682-7. PubMed ID: 19427146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII.
    Mukherjee J; DeSouza LV; Micallef J; Karim Z; Croul S; Siu KW; Guha A
    Cancer Res; 2009 Nov; 69(22):8545-54. PubMed ID: 19903856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
    Wikstrand CJ; McLendon RE; Friedman AH; Bigner DD
    Cancer Res; 1997 Sep; 57(18):4130-40. PubMed ID: 9307304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.